<code id='8870104A7E'></code><style id='8870104A7E'></style>
    • <acronym id='8870104A7E'></acronym>
      <center id='8870104A7E'><center id='8870104A7E'><tfoot id='8870104A7E'></tfoot></center><abbr id='8870104A7E'><dir id='8870104A7E'><tfoot id='8870104A7E'></tfoot><noframes id='8870104A7E'>

    • <optgroup id='8870104A7E'><strike id='8870104A7E'><sup id='8870104A7E'></sup></strike><code id='8870104A7E'></code></optgroup>
        1. <b id='8870104A7E'><label id='8870104A7E'><select id='8870104A7E'><dt id='8870104A7E'><span id='8870104A7E'></span></dt></select></label></b><u id='8870104A7E'></u>
          <i id='8870104A7E'><strike id='8870104A7E'><tt id='8870104A7E'><pre id='8870104A7E'></pre></tt></strike></i>

          entertainment

          entertainment

          author:focus    Page View:79
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi
          Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          Guidelines to prevent youth baseball injuries need more muscle
          Guidelines to prevent youth baseball injuries need more muscle

          Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

          read more

          Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

          TomDiLengeofFlagshipPioneering(left)withU.S.CongressmanRajaKrishnamoorthiofIllinoisata"techfair"desi